Use of the Medicinal Mushroom Agaricus Blazei Murill in Addition to High Dose Chemotherapy in Patients With Multiple Myeloma.
Patients who are scheduled to undergo high dose chemotherapy for multiple myeloma will
receive in addition in a double blinded manner 60 ml of agaricus extract or placebo once
daily from the start of stem cell mobilizing therapy until one week after the end of aplasia
after high dose melphalan.
Primary endpoints will be cytokine levels of degree of activation of tumor supressor genes
before and after start of the investigational product.
Secondary endpoints will be treatment response and quality of life.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cytokine levels in serum
Department of Hematology, Oslo University Hospital, Ulleval
Norway: Ethics Committee